1A80 Stock Overview
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Accelerate Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.86 |
| 52 Week High | US$9.10 |
| 52 Week Low | US$0.69 |
| Beta | 0.53 |
| 1 Month Change | -4.44% |
| 3 Month Change | -30.08% |
| 1 Year Change | -89.18% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1A80 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 7.5% | 2.6% | 1.2% |
| 1Y | -89.2% | -8.3% | 2.0% |
Return vs Industry: 1A80 underperformed the German Medical Equipment industry which returned -8.3% over the past year.
Return vs Market: 1A80 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 1A80 volatility | |
|---|---|
| 1A80 Average Weekly Movement | 12.4% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1A80's share price has been volatile over the past 3 months.
Volatility Over Time: 1A80's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 134 | Jack Phillips | acceleratediagnostics.com |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
Accelerate Diagnostics, Inc. Fundamentals Summary
| 1A80 fundamental statistics | |
|---|---|
| Market cap | €18.79m |
| Earnings (TTM) | -€57.47m |
| Revenue (TTM) | €11.25m |
1.7x
P/S Ratio-0.3x
P/E RatioIs 1A80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1A80 income statement (TTM) | |
|---|---|
| Revenue | US$12.06m |
| Cost of Revenue | US$9.51m |
| Gross Profit | US$2.55m |
| Other Expenses | US$64.17m |
| Earnings | -US$61.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.84 |
| Gross Margin | 21.15% |
| Net Profit Margin | -510.97% |
| Debt/Equity Ratio | -185.2% |
How did 1A80 perform over the long term?
See historical performance and comparison